American Journal of Kidney Diseases
Volume 49, Issue 2 , Pages 194-207 , February 2007

Target Level for Hemoglobin Correction in Patients With Diabetes and CKD: Primary Results of the Anemia Correction in Diabetes (ACORD) Study

Received 14 July 2006 ,Accepted 2 November 2006.

References 

  1. US Renal Data System: USRDS 2004 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004;
  2. Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant. 2003;18:1824–1833
  3. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care. 2004;27:15–35
  4. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146
  5. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  6. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884–890
  7. Parfrey PS, Harnett JD, Foley RN. Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hypertens. 1995;4:105–110
  8. Foley RN, Culleton BF, Parfrey PS, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia. 1997;40:1307–1312
  9. Arkouche W, Traeger J, Delawari E, et al. Twenty-five years of experience with out-center hemodialysis. Kidney Int. 1999;56:2269–2275
  10. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134
  11. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity—The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642–1644
  12. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study. Nephrol Dial Transplant. 2000;15:650–658
  13. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 2):S1–S249
  14. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):Sii1–Sii47
  15. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001;37:348–355
  16. Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: Variations across surrogates for quality of care and time. Nephron Clin Pract. 2005;101:c79–c86
  17. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002;40:1153–1161
  18. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–185
  19. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307–312
  20. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753–760
  21. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250–256
  22. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541–548
  23. Valderrabano F. Spanish Group for the Study of the Anaemia and Left Ventricular Hypertrophy in Predialysis Patients: Improvement and prevention of left ventricular hypertrophy in predialysis patients. J Am Soc Nephrol. 2000;11:0424A;(abstr)
  24. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med. 1999;16:813–819
  25. Rarick MU, Espina BM, Colley DT, Chrusoskie A, Gandara S, Feinstein DI. Treatment of a unique anemia in patients with IDDM with epoetin alfa. Diabetes Care. 1998;21:423–426
  26. ICH: Harmonised Tripartite Guideline: Guideline for Good Clinical Practice, adopted 1997. Available at: http://www.ich.org/UrlGrpServer.jser?@_ID=276&_TEMPLATE=254. Accessed April 2005
  27. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston, MA: The Health Institute; 1994;
  28. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903–912
  29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470
  30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  31. American Society of Echocardiography: Recommendations for continuous quality improvement in echocardiography. J Am Soc Echocardiogr. 1995;8(suppl P2):S1–S28
  32. National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis. 2006;47(suppl 3):S16–S85
  33. Radermacher J, Koch KM. Treatment of renal anemia by erythropoietin substitution (The effects on the cardiovascular system). Clin Nephrol. 1995;44(suppl 1):S56–S60
  34. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol. 1990;6:1–4
  35. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
  36. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–156
  37. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  38. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799–811
  39. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  40. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000;15:1425–1430
  41. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin >10 g/dL. Kidney Int. 2005;68:788–795
  42. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003;171:145–155
  43. Cruickshank JM, Pennert K, Sorman AE, Thorp JM, Zacharias FM, Zacharias FJ. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. J Hypertens. 1987;5:489–498
  44. Furberg CD, Cutler JA. Diuretic agents versus beta-blockers (Comparison of effects on mortality, stroke, and coronary events). Hypertension. 1989;13:157–161
  45. Lindholm LH, Hansson L, Ekbom T, et al. STOP Hypertension-2 Study Group Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens. 2000;18:1671–1675
  46. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  47. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  48. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738–750
  49. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;16:2071–2084

 Originally published online as doi:10.1053/j.ajkd.2006.11.032 on January 3, 2007.Support: The study was sponsored by F. Hoffmann-La Roche Ltd. Potential conflicts of interest: E.R. and D.O. received honoraria as speakers from Hoffmann-La Roche. A.S. and U.B. are employees of F. Hoffmann-La Roche Ltd.Trial registration: www.clinicaltrials.gov; study number: NCT00354341.

PII: S0272-6386(06)01706-9

doi: 10.1053/j.ajkd.2006.11.032

American Journal of Kidney Diseases
Volume 49, Issue 2 , Pages 194-207 , February 2007

Article Tools

* Image Usage & Resolution